Ignite Creation Date:
2025-12-25 @ 2:45 AM
Ignite Modification Date:
2026-04-16 @ 12:55 PM
Study NCT ID:
NCT06269133
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-27
First Post:
2024-02-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Sponsor:
Regeneron Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
R2810-ONC-22115
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None